Relationship between erb-B2 mRNA Expression in Blood and Tissue of Invasive Ductal Carcinoma Breast Cancer Patients and Clinicopathological Characteristics of the Tumors.

Molecular detection methods such as RT-PCR for detecting breast cancer-associated gene expression in the peripheral blood have the potential to modify breast cancer (BC) staging and therapy. In this regard, we evaluated the potential of erb-B2 molecular marker in BC detection and analyzed the expression of erb-B2 mRNA in the peripheral blood and fresh tissue samples of 50 pretreated female BC patients and 50 healthy females by reverse transcription-PCR (RT-PCR) method. We also assessed the correlation of erb-B2 mRNA marker positivity in peripheral blood and tumor tissue samples with clinical and pathological factors in BC patients in order to evaluate its prognostic value. It was shown that there is a significant difference between healthy females and BC patients with expression of the erb-B2 molecular marker (p<0.01). A significant difference between the expression of erb-B2 in the peripheral blood and tissue samples of BC patients (p<0.01) and the frequency of circulating erb-B2 mRNA expression in peripheral blood and in tissue was detected by RT-PCR. No correlation was found between erb-B2 mRNA expression in blood or tumor tissue samples and lymph node, tumor grade, tumor stage, tumor size, patient's age, ki67, estrogen receptor (ER), progesterone receptor (PGR), P53, and HER-2 status. However, in a small subset of 31 BC patients we found that expression of erb-B2 in peripheral blood or in both peripheral blood and tumor tissue was directly correlated with lympho-vascular invasion and perineural invasion as poor prognostic features. The highest rates of erb-B2 expression in peripheral blood or tumor tissue were in the ER and PR negative and HER-2 positive group. This study suggests that the application of the RT-PCR and immunohistochemical methods for erb-B2 molecular marker detection would provide a higher detection rate, especially in early stage BC.

McGill Quality of Life Questionnaire: reliability and validity of the Persian version in Iranian patients with advanced cancer.

OBJECTIVES: McGill Quality of Life Questionnaire (MQOL) is an instrument specifically designed to evaluate quality of life (QOL) in patients with advanced diseases. The primary objective of this study was to translate this questionnaire into Persian and assess its reliability and validity in Iranian patients suffering from an advanced cancer. The report also includes the correlations between patients' characteristics and their QOL scores. METHODS: MQOL was translated into Persian using a forward-backward method and administered to 62 patients with cancer at two hospitals in Tehran. Statistical analysis was performed to test reliability and validity of the questionnaire and to assess relationships between patients' characteristics and MQOL scores. RESULTS: In general, MQOL-Persian is a valid and reliable questionnaire to assess QOL in Iranian patients with advanced cancer. Test-retest reliability of the whole questionnaire is highly favorable for a questionnaire of this type (Pearson correlation = 0.87). Except for the existential subscale, all MQOL scores are internally consistent. There was no significant correlation between MQOL scores and patients' extent of knowledge about their disease. CONCLUSION: The Persian version of MQOL is, for the most part, a valid, reliable instrument in this setting. Because of cultural differences, the existential subscale may require adaptation. Further studies are needed to explore other aspects of QOL in Iranian patients with cancer.